Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Search for:

Recent Posts

Dupilumab (Dupixent®): CADTH Publishes Negative Recommendation for Reimbursement in Canada
Durvalumab (IMFENZI®): Follow up Approval for NSCLC in Japan
Call for Papers: Themed Issue – Improving Transparency in Decision Models
FDA to revisit guidelines for biosimilar development pathway
Anlotinib (Focus V®): First Global Approval – single-drug 3rd-line therapy for patients with advanced recurrent NSCLC

Recent Comments

	Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
	Durvalumab (IMFENZI®… on Durvalumab (IMFENZI®): Follow…
	Dupilumab (Dupixent®… on Dupilumab (Dupixent®): First G…
	Baricitinib (Olumian… on Baricitinib (Olumiant™): First…
	Revolution, innovati… on Using state-of-the-art technol…

Archives

Categories

Adis (78)
Adis Journals (86)
Adis Pharmacovigilance (21)
AdisInsight (89)
Uncategorized (2)

March 11, 2016 987 × 573

Adis_main_key_visual_red_FINAL

Leave a Reply Cancel reply

Powered by WordPress.com.